A Novel Automated Chemiluminescence Method for Detecting Cerebrospinal Fluid Amyloid-Beta 1-42 and 1-40, Total Tau and Phosphorylated-Tau: Implications for Improving Diagnostic Performance in Alzheimer’s Disease

A Novel Automated Chemiluminescence Method for Detecting Cerebrospinal Fluid Amyloid-Beta 1-42 and 1-40, Total Tau and Phosphorylated-Tau: Implications for Improving Diagnostic Performance in Alzheimer’s Disease

Recently, a fully automated instrument for the detection of the Cerebrospinal Fluid (CSF) biomarker for Alzheimer’s disease (AD) (low concentration of Amyloid-beta 42 (Aβ42), high concentration of total tau (T-tau) and Phosphorylated-tau (P-tau181)), has been implemented, namely CLEIA. We conducted...

Full description

Bibliographic Details
Main Authors:	Marina Arcaro, Chiara Fenoglio, Maria Serpente, Andrea Arighi, Giorgio G. Fumagalli, Luca Sacchi, Stefano Floro, Marianna D’Anca, Federica Sorrentino, Caterina Visconte, Alberto Perego, Elio Scarpini, Daniela Galimberti
Format:	Article
Language:	English
Published:	MDPI AG 2022-10-01
Series:	Biomedicines
Subjects:	CSF biomarkers Alzheimer’s disease ELISA CLEIA
Online Access:	https://www.mdpi.com/2227-9059/10/10/2667

Similar Items

Association between enlarged perivascular spaces and cerebrospinal fluid aquaporin-4 and tau levels: report from a memory clinic
by: Luca Sacchi, et al.
Published: (2023-07-01)

Development of a New Chemiluminescent Enzyme Immunoassay Using a Two-Step Sandwich Method for Measuring Aldosterone Concentrations
by: Yoshinori Ozeki, et al.
Published: (2021-03-01)

Plasma tau complements CSF tau and P‐tau in the diagnosis of Alzheimer's disease
by: Silvia Fossati, et al.
Published: (2019-12-01)

ELISA and Chemiluminescent Enzyme Immunoassay for Sensitive and Specific Determination of Lead (II) in Water, Food and Feed Samples
by: Long Xu, et al.
Published: (2020-03-01)

Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis
by: Débora Lanznaster, et al.
Published: (2020-04-01)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
by: Kristi Henjum, et al.
Published: (2018-11-01)

Circulating Non-Coding RNA Levels Are Altered in Autosomal Dominant Frontotemporal Dementia
by: Chiara Fenoglio, et al.
Published: (2022-11-01)

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)
by: Hugo Vanderstichele, et al.
Published: (2017-06-01)

Cerebrospinal fluid Aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis
by: Zhongyun Chen, et al.
Published: (2017-05-01)

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke
by: Ann De Vos, et al.
Published: (2017-08-01)

Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes
by: Tiziana Carandini, et al.
Published: (2019-10-01)

Aquaporin-4 cerebrospinal fluid levels are higher in neurodegenerative dementia: looking at glymphatic system dysregulation
by: Andrea Arighi, et al.
Published: (2022-09-01)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
by: Rik Ossenkoppele, et al.
Published: (2021-08-01)

Re-Assessment of the Oral Salt Loading Test Using a New Chemiluminescent Enzyme Immunoassay Based on a Two-Step Sandwich Method to Measure 24-Hour Urine Aldosterone Excretion
by: Yoshinori Ozeki, et al.
Published: (2022-03-01)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
by: Juan Lantero-Rodriguez, et al.
Published: (2023-03-01)

MiRNA Profiling in Plasma Neural-Derived Small Extracellular Vesicles from Patients with Alzheimer’s Disease
by: Maria Serpente, et al.
Published: (2020-06-01)

Genome-wide network-based pathway analysis of CSF t-tau/Aβ1-42 ratio in the ADNI cohort
by: Wang Cong, et al.
Published: (2017-05-01)

Tau kinetics in Alzheimer's disease
by: Daniel B. Hier, et al.
Published: (2022-11-01)

SARS-CoV-2 Omicron detection by antigen tests using saliva
by: Kaoru Murakami, et al.
Published: (2022-11-01)

24S-Hydroxycholesterol Correlates With Tau and Is Increased in Cerebrospinal Fluid in Parkinson's Disease and Corticobasal Syndrome
by: Ingemar Björkhem, et al.
Published: (2018-09-01)

Production and characterization of a single-chain Fv antibody–alkaline phosphatase fusion protein specific for ampicillin
by: Kuo He, et al.
Published: (2019-01-01)

Effect of long‐term storage in biobanks on cerebrospinal fluid biomarker Aβ1‐42, T‐tau, and P‐tau values
by: Eline A.J. Willemse, et al.
Published: (2017-01-01)

Extracellular Vesicles in Multiple Sclerosis: Role in the Pathogenesis and Potential Usefulness as Biomarkers and Therapeutic Tools
by: Marianna D’Anca, et al.
Published: (2021-07-01)

Serum tau protein elevation in migraine: a cross-sectional case–control study
by: Lucas Hendrik Overeem, et al.
Published: (2023-09-01)

SARS-CoV-2 Surveillance in Hospital Wastewater: CLEIA vs. RT-qPCR
by: Supranee Thongpradit, et al.
Published: (2023-07-01)

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
by: Juan Lantero‐Rodriguez, et al.
Published: (2021-12-01)

Caspase-1 variant influencing CSF tau and FDG PET levels in non-demented elders from the ADNI cohort
by: Yi Liu, et al.
Published: (2022-02-01)

Exosome Determinants of Physiological Aging and Age-Related Neurodegenerative Diseases
by: Marianna D’Anca, et al.
Published: (2019-08-01)

Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
by: Flora H. Duits, et al.
Published: (2021-01-01)

The Influence of Cerebrospinal Fluid Abnormalities and APOE 4 on PHF-Tau Protein: Evidence From Voxel Analysis and Graph Theory
by: Yuan Li, et al.
Published: (2019-08-01)

Prediction of rapid amyloid and phosphorylated‐Tau accumulation in cognitively healthy individuals
by: Ivan Koychev, et al.
Published: (2020-01-01)

Hearing impairment is associated with cognitive decline, brain atrophy and tau pathologyResearch in context
by: Hui-Fu Wang, et al.
Published: (2022-12-01)

CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease
by: Jeremy F. Strain, et al.
Published: (2022-06-01)

Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease
by: Mahsa Dolatshahi, et al.
Published: (2018-07-01)

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
by: Ross W. Paterson, et al.
Published: (2015-09-01)

Whole‐brain DTI parameters associated with tau protein and hippocampal volume in Alzheimer's disease
by: Thamires Naela Cardoso Magalhães, et al.
Published: (2023-02-01)

Altered Extracellular Vesicle miRNA Profile in Prodromal Alzheimer’s Disease
by: Caterina Visconte, et al.
Published: (2023-09-01)

Performance of biomarkers NF-L, NSE, Tau and GFAP in blood and cerebrospinal fluid in rat for the detection of nervous system injury
by: Katerina Vlasakova, et al.
Published: (2024-01-01)

Profiles of 14-3-3 and Total Tau in CSF Samples of Chinese Patients of Different Genetic Prion Diseases
by: Cao Chen, et al.
Published: (2019-09-01)

Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels
by: Taylor J. Maxwell, et al.
Published: (2018-08-01)